Psoriatic Arthritis
Conference Coverage
Get ready for certolizumab for psoriasis
KAUAI, HAWAII – Women of childbearing potential may prefer it.
From the Journals
CV risk factors go undiagnosed, untreated in many psoriatic patients
Study of more than 2,000 patients at eight centers in Canada, the United States, and Israel.
Latest News
Make a PEST of your psoriasis patients
KAUAI, HAWAII – Every psoriasis patient should complete the Psoriasis Epidemiology Screening Tool (PEST) for psoriatic arthritis annually.
Conference Coverage
Meta-analysis: Lifestyle changes improve psoriasis
GENEVA – Obese patients can reduce psoriasis severity and boost quality of life with diet or exercise.
Conference Coverage
Ixekizumab beats ustekinumab for fingernail psoriasis, hands down
GENEVA – Clear nails in half of ixekizumab users by week 24.
From the Journals
Novel herpes zoster vaccine is more cost effective than old vaccine
Cost-effectiveness can be an important factor in considering patient treatment for herpes zoster.
Conference Coverage
Prior biologic exposure doesn’t diminish ixekizumab’s efficacy
GENEVA – Ixekizumab works “extraordinarily well” for psoriasis – even with prior exposure to other IL-17 inhibitors.
News
FDA approves tofacitinib for psoriatic arthritis
The drug is now the only Janus kinase inhibitor approved to treat psoriatic arthritis.
Conference Coverage
Guselkumab crushes skin disease in psoriatic arthritis patients
GENEVA – IL-23 inhibitor achieves consistent skin outcomes in psoriasis with and without arthritis.
News
FDA approves infliximab biosimilar Ixifi for all of Remicade’s indications
It is the third biosimilar of Remicade to be approved by the FDA.
Opinion
Testing for latent tuberculosis infection
The newest recommendations focus on when and for whom it is best to use the tuberculin skin test, Interferon Gamma Release Assay, or both.